An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria.
Reuling IJ, Mendes AM, de Jong GM, Fabra-García A, Nunes-Cabaço H, van Gemert GJ, Graumans W, Coffeng LE, de Vlas SJ, Yang ASP, Lee C, Wu Y, Birkett AJ, Ockenhouse CF, Koelewijn R, van Hellemond JJ, van Genderen PJJ, Sauerwein RW, Prudêncio M.
Reuling IJ, et al. Among authors: de jong gm, de vlas sj.
Sci Transl Med. 2020 May 20;12(544):eaay2578. doi: 10.1126/scitranslmed.aay2578.
Sci Transl Med. 2020.
PMID: 32434846
Clinical Trial.